BACKGROUND
New interferon (IFN)free hepatitis c virus (HCV) therapies offer better viral clearance rates and fewer • adverse events (AEs) than older HCV therapies, but are priced higher. These therapies have also been shown to have favorable costeffectiveness profiles compared with older • therapies; however, the costeffectiveness of IFNfree regimens relative to each other is unclear.
OBJECTIVE
To determine the costeffectiveness of treating genotype (GT)1HCV with AbbVie 3D • (paritaprevir/ritonavir/ombitasvir and dasabuvir) with or without ribavirin (RBV) compared with sofosbuvir + ledipasvir (SOF+LDV) in the United States.
METHODS

Model Structure
A Markov costeffectiveness model was used to determine the costeffectiveness of 3D ± RBV treatment • compared to SOF+LDV. Liver disease progression was assessed based on the natural history model (Figure 1) Treatment Efficacy SVR data were obtained from the clinical trials data using arms related to FDAapproved labels for each • regimen.
Overall efficacy was estimated as the average SVR rates weighted by the proportion of patients stratified • by treatment duration, treatment history, cirrhosis status, and subgenotype, based on pooled data in SAPPHIRE I, II, PEARL II, III, IV, and TURQUOISE II for 3D ± RBV and ION 1, 2, and 3 for SOF+LDV (Table 2) . 26%* of treatmentnaïve, noncirrhotic patients on SOF+LDV treatment were assumed to have received 8 weeks of therapy. 
Health Utility Weights
Qualityadjusted life years (QALYs) were calculated using estimates of health utility in different health • states before and after treatment. Health statebased utility weights reflected the expected annual quality of life in each health state • associated with untreated chronic HCV1. AbbVie regimen disutility was based on EQ5D scores recorded in clinical trials; SOF+LDV was assumed • to be the same.
Costs
Costs included: • Direct medical costs by health state (Table 3 ) -Regimen costs, defined as the cost associated with direct drug costs only (Table 4 ) -AE costs, defined as the cost associated with regimenrelated AEs identified in the trials ( 
Model Analysis
Costs and outcomes (e.g., QALYs) were discounted at 3%.
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• The model had a lifetime horizon and used US lifetablederived annual background mortality • probabilities. Deteriministic sensitivity analysis and probabilistic sensitivity analyses (PSA) were estimated.
•
The PSA used a net monetary benefits (NMB) framework valuing QALYs at $100,000 each • NMB = $100,000*(QALYs ABV QALYs SOF+LDV )(Costs ABV Costs SOF+LDV ).
Outcomes
Effects were measured in QALYs.
• Costeffectiveness was quantified as incremental costeffectiveness ratios (ICERs). • RESULTS HCV treatmentrelated costs were lower with 3D ± RBV versus SOF+LDV in all patient segments (Figure 2 ).
• 3D ± RBV also resulted in increased QALYs versus SOF+LDV in the overall, treatmentnaïve, treatment • experienced, and all noncirrhotic patient segments (Figure 2 ). 3D ± RBV dominated SOF+LDV in the overall, treatmentnaïve, treatmentexperienced, and noncirrhotic • segments. 3D ± RBV was more costeffective than SOF+LDV in the cirrhotic segment, assuming a costeffectiveness • threshold of $100,000/QALY. The PSA demonstrated that these results were robust to multivariate uncertainty. 
